Diabetes diagnoses are skyrocketing and insulin purchases have more than tripled since 2003. Yet innovation has lagged and current insulin products start coming off patent in 2014. That is why we formed Thermalin Diabetes.
Thermalin’s lead product is a highly concentrated, rapid acting insulin with the potential to dramatically change the lives of millions of people with type II and type I diabetes across the globe.
The Thermalin Team includes players who have significantly influenced the world of insulin for over 30 years. Founder Michael Weiss has published over 150 peer reviewed articles (more than half on insulin) and VP of Development Bruce Frank is a co-inventor of Humalog, the first ever fast acting insulin. Thermalin will initiate its phase Ia clinical study and is uniquely positioned to reach a major value inflection point at a time when there will be a high demand for new insulin products.
Thermalin Funded to Develop Novel New Insulins
Dr. Weiss Honored for Exemplary Research Contributions
Thermalin awarded $1.5M Phase II SBIR Grant for Fluorolog.
Insulin startup Thermalin gets JDRF support for an ultra rapid-acting insulin for T1D
Get in Touch